Follow Abbott Laboratories to never miss an important update.
Abbott notified its top executives on November 11 that it is extending their change-in-control agreements through the end of 2028. These are contracts that provide payouts or protections to leaders if the company is bought or its ownership changes. While most named executive officers received the extension, the company noted that Chairman and CEO Robert B. Ford's agreement will expire on December 31, 2026. This is a technical shift in how the CEO is covered compared to his team, but it does not change his current role leading the company's transition toward medical technology.
Source: 8-K filing
New data from a year-long study show that Abbott's Amulet 360 device is highly effective at closing the left atrial appendage, a small pouch in the heart where blood clots often form. By sealing this area, the device helps prevent strokes in patients with an irregular heartbeat who cannot take long-term blood thinners.
These results are important because they support Abbott's push into more advanced heart care hardware. As the company moves toward becoming a specialized medical technology business, proving the long-term safety and success of its newer devices is key to winning over doctors and taking market share from rivals.
Source: PRNewsWire
Abbott reported positive 30-day results for its SonicForce system, which uses acoustic pressure waves to crack calcium buildup in heart arteries. This technique, known as lithotripsy, is similar to how doctors break up kidney stones and allows blood to flow more freely without the need for more invasive surgery.
While this was an early-stage trial, the high success rate and lack of complications are promising for Abbott's coronary device business. If this system eventually wins full approval, it would give the company a more modern tool for treating complex heart disease, which is a core part of its long-term growth plan.
Source: PRNewsWire
Abbott has started a pivotal trial for Cephea, a device designed to replace the heart's mitral valve without the need for open-heart surgery. Mitral valve disease is the most common heart valve problem, and this trial will test how safely and effectively the device works in patients who need a replacement.
This is a key step in Abbott's shift toward becoming a focused medical technology company. If successful, Cephea would expand its heart care business by offering a less invasive option for a condition that affects millions of people. While the trial will take time to complete, it shows the company is continuing to build out its pipeline of high-tech hardware.
Source: PRNewsWire
Argus Research changed its rating from Buy to Hold on Tuesday. This shift comes just a week after the company announced it would spin off its nutrition business, which includes brands like Similac, to focus more on medical devices and heart care.
While the average analyst target remains higher at about $121, this move suggests some caution about the transition period ahead. The spin-off is intended to make the company a faster-growing medical technology specialist, but it also removes the steady cash flow that the nutrition segment provided during tougher economic times.
Source: Argus Research
Management has matched or slightly exceeded its own profit targets for two straight years. This consistency shows they have a tight grip on their costs and set bars they are certain to clear.
| Expectation | |
|---|---|
| EPS | $1.64 |
| Revenue | $13.21B |
Follow Abbott Laboratories to get the latest and most important updates.
Follow ABT